Control of Helicobacter Pylori Infection by Probiotics

This study is currently recruiting participants.
Verified August 2012 by University of Bari
Sponsor:
Information provided by (Responsible Party):
Ruggiero Francavilla, University of Bari
ClinicalTrials.gov Identifier:
NCT01115296
First received: April 28, 2010
Last updated: August 16, 2012
Last verified: August 2012
  Purpose

Helicobacter pylori colonises an estimated 50% of the world´s population (Taylor & Blaser, 1991; Go, 2002). Despite clear clinical guidelines on the treatment of this infection (Malfertheiner et al. 2007) there is a drive to find alternative ways to control this infection in a wider perspective without the complications of induction of antibiotic resistance in the pathogen.

L. reuteri has been widely studied in clinical trials and has been shown to have probiotic, health-promoting effects in both adults and children (Connolly 2004; Casas & Dobrogosz, 2000). L. reuteri has been shown in numerous studies to be safe for human consumption and it has been shown to colonise the human gastrointestinal tract (Wolf et al., 1995, Valeur et al., 2004).

Studies using supplementation with L. reuteri in both symptomatic and non-symptomatic H. pylori-infected subjects show a clear reduction of infection load after 4 weeks of use and this was concomitant with a reduction in symptoms associated with the infection (Imase et al. 2007; Francavilla et al. 2007, unpublished data). Further, dietary supplementation with L. reuteri during and after the period of H. pylori eradication therapy has also been shown to reduce the side effects of this therapy without affecting the degree of eradication (Lionetti et al., 2007). It is also feasible, through the inhibitory action of L. reuteri on H. pylori, that pre-exposure to L. reuteri may weaken H. pylori and make it more susceptible to antibiotic attack during eradication.

However, an earlier pilot study was not been able to demonstrate a reduction in gastric inflammation caused by H. pylori. This pilot study was performed with L. reuteri ATCC 55730 that has since been found to lack anti-inflammatory activity in in vitro screens. Recent selection of natural, human L. reuteri strains has identified a specific strain with strong anti-inflammatory properties in vitro (Lin et al, 2007 and submitted 2007). A combination of this strain, together with the earlier proven L. reuteri strain, is expected to lead to both a reduction of H. pylori load as well as a reduction in the gastric inflammation related to the pathogen.


Condition Intervention
Helicobacter Pylori Infection
Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475
Other: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Control of Helicobacter Pylori Infection by Dietary Supplementation With Lactobacillus Reuteri

Resource links provided by NLM:


Further study details as provided by University of Bari:

Primary Outcome Measures:
  • to decrease H. pylori gastric load [ Time Frame: 28 days ] [ Designated as safety issue: No ]

    Primary Outcome Measures:

    Decrease H. pylori gastric load by histology after 28 days compared to placebo and by 13C-UBT compared to placebo.



Secondary Outcome Measures:
  • To decrease dyspeptic symptoms [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    To decrease dyspeptic symptoms before, during and after eradication therapy as assessed by a gastro-intestinal symptom rating scale


Estimated Enrollment: 100
Study Start Date: January 2010
Estimated Study Completion Date: August 2012
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 'L. reuteri DSM 17938 and ATCC PTA 6475
L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.
Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475
L. reuteri dose of 1x108 CFU.
Other Name: Probiotic mixture
Placebo Comparator: Placebo
Placebo
Other: Placebo
Placebo
Other Name: Placebo identical to active

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects aged 18 - 65 years
  • Infection with H. pylori defined as ∆ > 20 ppm in the UBT test
  • Non-ulcer dyspepsia
  • No earlier eradication therapy for H. pylori infection
  • Written informed consent
  • Stated availability throughout the entire study period
  • Mental ability to understand and willingness to fulfil all the details of the protocol.

Exclusion Criteria:

  • Duodenal or gastric ulcer
  • MALT lymphoma
  • Gastric resection (at any time)
  • First level relatives of gastric cancer patients
  • Absence of GI symptoms
  • Use of NSAIDs, aspirin or other anti-inflammatory drugs within 1 week (for occasional use) or 3 weeks (for chronic use) of inclusion
  • Use of oral antibiotics and/or PPIs and/or H2-antagonists during the 2 weeks prior to ingestion of the study product
  • Pregnancy
  • Participation in other clinical trials
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01115296

Contacts
Contact: Ruggiero Francavilla, MD, PhD +390805592063 ext 2847 rfrancavilla@libero.it

Locations
Italy
Unit of Gastroenterology Recruiting
Bari, Italy, 70100
Contact: Beatrice Principi, MD    +390805592869      
Sponsors and Collaborators
University of Bari
Investigators
Principal Investigator: Principi Beatrice, MD University of Bari
  More Information

Publications:
Responsible Party: Ruggiero Francavilla, MD, PhD, University of Bari
ClinicalTrials.gov Identifier: NCT01115296     History of Changes
Other Study ID Numbers: HP-Progastria
Study First Received: April 28, 2010
Last Updated: August 16, 2012
Health Authority: Italy: Ethics Committee

Keywords provided by University of Bari:
Helicobacter Pylori
gastritis
Probiotics
Lactobacillus Reuteri

Additional relevant MeSH terms:
Helicobacter Infections
Gram-Negative Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on April 15, 2014